AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33048260
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics (1 g of amoxicillin, twice daily for 7 days)
Trial: 32997386
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (control)
Trial: 35914262
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral therapy (CBT) with interoceptive exposure
Trial: 32154636
Drug: Gilteritinib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gilteritinib (120 mg once daily)
Trial: 37644897
Drug: THC 20
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THC 20 mg
Trial: 33326356
Drug: ALIS+GBT (590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALIS+GBT (590 mg once-daily for 12 months)
Trial: 34325483
Drug: Withdrawal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal and early preventive medication (W+P)
Trial: 34325483
Drug: Preventives with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventives with potential withdrawal therapy after 6 months (P+pW)
Trial: 34325483
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment effect (all groups combined)
Trial: 33221559
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 gm if body weight <90 kg, 1.5 g if body weight >90 kg)
Trial: 33221559
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 ml of distilled water in 15 ml of 5% dextrose)
Trial: 33053279
Drug: BNT162b2 (lipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 (lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidate)
Trial: 33053279
Drug: BNT162b1 (lipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b1 (lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidate)
Trial: 35907513
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg by mouth 3 times a day for 30-36 months
Trial: 32948827
Drug: bissap tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bissap tablets (2 × 375 mg/day)
Trial: 32948827
Drug: bissap brew
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bissap brew (10 g of calyx/day)
Trial: 32948827
Drug: kinkeliba tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: kinkeliba tablets (2 × 200 mg/day)
Trial: 32948827
Drug: kinkeliba brew
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: kinkeliba brew (10 g of leaves/day)
Trial: 32948827
Drug: captopril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: captopril (2 × 50 mg/day)
Trial: 33443933
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) administered before surgery and at various time points postoperatively.
Trial: 33443933
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered before surgery and at various time points postoperatively.
Trial: 33443933
Drug: Oral TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TXA (1g) taken by healthy volunteers.
Trial: 35605268
Drug: Flurbiprofen 8.75
RxNorm normalized name: flurbiprofen 8.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 8.75 mg and cetylpyridinium chloride 1.00 mg in the form of tablets for resorption
Trial: 36404687
Drug: Cetylpyridinium chloride
RxNorm normalized name: Cetylpyridinium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetylpyridinium chloride 1.2 mg in the form of medicinal lozenges
Trial: 32846782
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg dexamethasone (4 mL) intravenously just after anesthesia and repeated at 24 hours after surgery
Trial: 32846782
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dexamethasone (2 mL) intravenously just after anesthesia and repeated at 24 hours after surgery
Trial: 34175463
Drug: Performing rectal
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Performing rectal sutures within 8 cm from the anal verge
Trial: 33648834
Drug: Sodium 4-phenylbutyrate
RxNorm normalized name: 4-phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium 4-phenylbutyrate (NaPB) high dose (4.3 g/m2) administered pre-breakfast
Trial: 33648834
Drug: Sodium 4-phenylbutyrate
RxNorm normalized name: 4-phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium 4-phenylbutyrate (NaPB) low dose (1.4 g/m2) administered pre-breakfast
Trial: 33648834
Drug: Sodium 4-phenylbutyrate
RxNorm normalized name: 4-phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium 4-phenylbutyrate (NaPB) administered post-breakfast (both doses)
Trial: 35863990
Drug: Single CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single CO2 laser treatment
Trial: 38828109
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp)
Trial: 35831046
Drug: Concurrent consent
RxNorm normalized name: Consensi
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent consent during in‐person assessment for health data
Trial: 35831046
Drug: Concurrent consent
RxNorm normalized name: Consensi
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent consent during in‐person assessment for education data
Trial: 33010045
Drug: Mentalization‐Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization‐Based Treatment (MBT)
Trial: 35284808
Drug: 1 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 µg
Trial: 35284808
Drug: 1 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 µg + CpG1018
Trial: 35284808
Drug: 3 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 µg
Trial: 35284808
Drug: 3 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 µg + CpG1018
Trial: 35284808
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg
Trial: 34011035
Drug: Bailing Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bailing Capsule (BC) combined with α-ketoacid tablets (KA)
Trial: 34011035
Drug: BC-simulation combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BC-simulation combined with α-ketoacid tablets (KA)
Trial: 32921794
Drug: CBD (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (600 mg)
Trial: 36164037
Drug: R-CHOP +
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP + tafasitamab (12 mg/kg IV, D1, 8, 15)
Trial: 36164037
Drug: R-CHOP +
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP + tafasitamab + lenalidomide (25 mg orally, D1-10)
Trial: 32989825
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (50 mg/kg−1)
Trial: 32989825
Drug: Systemic tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic tranexamic acid (20 mg/kg−1 through cardiopulmonary bypass and another 20 mg/kg−1 after separation)
Trial: 34399759
Drug: iStent inject®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iStent inject® + concurrent cataract surgery
Trial: 32464421
Drug: Moringa oleifera
RxNorm normalized name: Moringa Oleifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa oleifera leaves extract (MOLE) at a dose of 40 mg/kg orally daily
Trial: 32464421
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E and selenium at a dose of 3 ml (4.5 mg sodium selenite and 204 mg vitamin E)/head i.m twice a week for 64 days
Trial: 32472001
Drug: Olaparib tablets
RxNorm normalized name: Olaparib Tablets
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib tablets (300 mg twice daily)
Trial: 35598114
Drug: Chloroquine alone
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine alone (600 mg base)
Trial: 35598114
Drug: Chloroquine with
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine with azithromycin (500 mg)
Trial: 35598114
Drug: Chloroquine with
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine with azithromycin (1,000 mg)
Trial: 35598114
Drug: Chloroquine with
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine with azithromycin (1,500 mg)
Trial: 32614987
Drug: IncoA intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncoA intradermal injection (100 unit or 1 vial in 6 cc of NSS)
Trial: 32614987
Drug: IncoA intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncoA intradermal injection
Trial: 33788485
Drug: Thumbtack needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thumbtack needling therapy
Trial: 36036107
Drug: Sham-thumbtack needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-thumbtack needling therapy
Trial: 36036107
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (PCA)
Trial: 32423457
Drug: Differed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differed treatment program
Trial: 33148686
Drug: Dextrose gel
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose gel (buccal 40% dextrose gel)
Trial: 32040014
Drug: CYD‐TDV (tetravalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYD‐TDV (tetravalent dengue vaccine)
Trial: 36070590
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) with LED irradiation
Trial: 36357085
Drug: TEER plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEER plus guideline-directed medical therapy (GDMT)
Trial: 33390654
Drug: Inhaled glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticoids (fluticasone)
Trial: 38670610
Drug: Oral glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucocorticoids
Trial: 36303867
Drug: Nomogram including
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nomogram including variables such as radiotherapy, primary site surgery, Ann Arbor Stage, chemotherapy, histological subtype, and age at diagnosis.
Trial: 34737091
Drug: Lofexidine (alpha-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofexidine (alpha-2 adrenergic agonist)
Trial: 33533820
Drug: Early therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early therapy (rehabilitative protocol started immediately after the initial evaluation)
Trial: 33533820
Drug: Late therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late therapy (rehabilitative protocol started 10 weeks later)
Trial: 35886189
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) (50 hr, 25 session)
Trial: 32067249
Drug: AZD0284 (4-238
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0284 (4-238 mg single dose or 12-100 mg multiple doses)
Trial: 35918313
Drug: Suvorexant (SUV);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant (SUV); 10 mg
Trial: 35367136
Drug: Mixed allergenic
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed allergenic food powder (MP) containing egg, milk, wheat, soybean, buckwheat, and peanuts, administered in increasing amounts until week 12
Trial: 36290823
Drug: Nutritional counseling
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional counseling provided by registered dietitians at least every two weeks during antineoplastic treatment
Trial: 34953531
Drug: Oral octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral octreotide (40 mg a day, optional titration to 60 or 80 mg a day)
Trial: 34953531
Drug: Injectable somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable somatostatin receptor ligands (iSRLs) at the same dose and interval as before enrolment
Trial: 34953531
Drug: Oral octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral octreotide
Trial: 34953531
Drug: Injectable somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable somatostatin receptor ligands (iSRLs)
Trial: 33612449
Drug: Antifibrinolytics and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifibrinolytics and plasma products (including intravenous immunoglobulin)
Trial: 33536271
Drug: Low-dose vs
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vs Standard-dose alteplase
Trial: 35398218
Drug: PF-06826647 200
RxNorm normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-06826647 200 mg
Trial: 38279383
Drug: PF-06826647 400
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06826647 400 mg
Trial: 34261093
Drug: Long-acting therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting therapy (cabotegravir with rilpivirine, dosed every 4 weeks)
Trial: 34261093
Drug: Switch arm
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch arm (transition from current antiretroviral therapy to long-acting therapy)
Trial: 34261093
Drug: Long-acting therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting therapy (cabotegravir with rilpivirine)
Trial: 35183744
Drug: Topical pHisoHex
RxNorm normalized name: Phisohex
DrugBank: Hexachlorophene (DB00756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical pHisoHex (hexachlorophene [1% triclosan; sodium benzoate, 5 mg/mL; and benzyl alcohol, 5 mg/mL])
Trial: 34363558
Drug: gilteritinib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gilteritinib (120 mg/day)
Trial: 34363558
Drug: salvage chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salvage chemotherapy (SC)
Trial: 32164886
Drug: Liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.8 mg daily or maximum tolerated dose up to 1.8 mg daily)
Trial: 34143186
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (Amoxicillin & Clavulanic Acid)
Trial: 37545861
Drug: GV1001 1.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GV1001 1.12 mg
Trial: 33771205
Drug: GV1001 0.56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GV1001 0.56 mg
Trial: 35063242
Drug: Cornelian cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cornelian cherry fruit extract (20 cc/d for 12 weeks)
Trial: 35063242
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 cc/d for 12 weeks)
Trial: 33109935
Drug: Control participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control participants received treatment as usual.
Trial: 36266930
Drug: Occupational Performance
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational Performance Coaching (OPC) - eight weekly sessions
Trial: 35606886
Drug: TF‐CBTp +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TF‐CBTp + treatment as usual (TAU)
Trial: 33788296
Drug: MD+LPS (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD+LPS (5 mg/kg)
Trial: 33788296
Drug: Control+LPS (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control+LPS (5 mg/kg)
Trial: 35606010
Drug: Molnupiravir, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molnupiravir, a novel antiviral medicine aimed at reducing the ability of SARS-CoV-2 to multiply in the body.
Trial: 35842120
Drug: Hydronidone 180
RxNorm normalized name: Hydronidone
DrugBank: Hydronidone (DB06299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydronidone 180 mg/day
Trial: 35842120
Drug: Hydronidone 270
RxNorm normalized name: Hydronidone
DrugBank: Hydronidone (DB06299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydronidone 270 mg/day
Trial: 35842120
Drug: Hydronidone 360
RxNorm normalized name: Hydronidone
DrugBank: Hydronidone (DB06299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydronidone 360 mg/day
Trial: 36089558
Drug: Buzzy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buzzy and cold spray
Trial: 34726849
Drug: Control treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatments (sponge floss only, ultrasonic device with polyetheretherketone fibre tip coating, and manual scaling with carbon fibre curettes and use of sponge floss)
Trial: 34130550
Drug: ω‐3 fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 fish oil (3200 mg/day)
Trial: 32889959
Drug: Bioenhanced curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioenhanced curcumin (BEC) 50 mg twice daily
Trial: 32575441
Drug: Pomegranate extract
RxNorm normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate extract 20 mL (720 mg phenolic compounds) for two weeks
Trial: 35761219
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma plus standard therapy (CP + ST)
Trial: 35761219
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy alone (ST)
Trial: 32183736
Drug: Neoadjuvant laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC
Trial: 32183736
Drug: Standard R0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard R0 D2 followed by 8 cycles of adjuvant chemotherapy (AC) with oxaliplatin and S-1 (SOX) regimen
Trial: 34327732
Drug: Hydroxychloroquine (2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (2400 mg over 5 days)
Trial: 34787823
Drug: Weekly dulaglutide
RxNorm normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dulaglutide doses for 4 weeks
Trial: 34091608
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus bronchoscopic suction every other day
Trial: 34091608
Drug: Antibiotics with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics with daily closed-suction
Trial: 32660791
Drug: Replacing 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replacing 100 g/day of fried food with non-fried food
Trial: 32660791
Drug: Replacing 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replacing 100 g/day of fried protein-rich food
Trial: 32660791
Drug: Replacing 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replacing 100 g/day of fried eggs
Trial: 32660791
Drug: Replacing 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replacing 100 g/day of fried fish
Trial: 34343658
Drug: Daratumumab (Dara)
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab (Dara) with or without standard chemotherapy
Trial: 34343658
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (as a control)
Trial: 32018062
Drug: Remestemcel-L therapy
RxNorm normalized name: remestemcel-L
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remestemcel-L therapy (2 × 10^6 cells/kg twice weekly for 4 weeks)
Trial: 32018062
Drug: Remestemcel-L therapy
RxNorm normalized name: remestemcel-L
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remestemcel-L therapy
Trial: 36103288
Drug: Dermolina-Henna cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermolina-Henna cream
Trial: 36103288
Drug: Mometasone cream
RxNorm normalized name: mometasone Topical Cream
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone cream
Trial: 36235569
Drug: BSG extract-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSG extract-based food supplement
Trial: 32158971
Drug: Continuous antibiotic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous antibiotic prophylaxis (CAP) until hydronephrosis resolution or aged 12 months (n=40)